Also known as: Evenity, EVENITY
Evenity (romosozumab-aqqg) is a sclerostin inhibitor biologic for postmenopausal women with osteoporosis at high fracture risk, including those with prior fracture history, multiple risk factors, or failure/intolerance of other therapies. Treatment duration is limited to 12 monthly doses with subsequent anti-resorptive therapy consideration. It carries a boxed warning for cardiovascular risk.
Barclays initiated Amgen with an Equal Weight rating and a $185 price target as debate over the Phase 3 MARITIME trial continued. Amgen said 2025 revenue and earnings per share rose by double digits.
Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.
